Citations

Clear

4847 citation(s) found for "Tu, Eric".

Can we prevent Alzheimer's disease? Secondary “prevention” trials in Alzheimer's disease
Carrillo, María C. , Brashear, H. Robert, Logovinsky, Veronika, Ryan, J. Michael, Feldman, Howard , Siemers, Eric , Abushakra, Susan, Hartley, Dean M. , Petersen, Ronald C. , Khachaturian, Ara S. , Sperling, Reisa Anne , Feldman, Howard H

Mayo Clinic

Alzheimer's & Dementia | February 11, 2013 | Volume: 9 | Issue: 2 | Pages: 123

10.1016/j.jalz.2012.12.004 | PMID 23411394 Get It

Current research including the basic biology of Alzheimer's disease (AD) provides a foundation to explore whether our current state of knowledge is sufficient to initiate prevention studies and allow us to believe prevention of AD is possible. Current research and recently revised criteria for the diagnosis of AD by the National Institutes on Aging and the Alzheimer's Association suggest a continuum of disease from preclinical asymptomatic to symptomatic Alzheimer's dementia. In light of these revised criteria, the possibility of secondary prevention and even primary prevention is under discussion. The Alzheimer's Association Research Roundtable convened a meeting to discuss the rationale and feasibility of conducting secondary prevention trials in AD.
The Role of Diazepam Loading for the Treatment of Alcohol Withdrawal Syndrome in Hospitalized Patients
Muzyk, Andrew J. , Leung, Jonathan G. , Embury, Eric R., Jones, Sharon, Nelson, Sarah E. , Leung, Jonathan G

Mayo Clinic

The American Journal on Addictions | February 1, 2013 | Volume: 22 | Issue: 2 | Pages: 113-118

10.1111/j.1521-0391.2013.00307.x | PMID 23414495 Get It

BackgroundAlcohol withdrawal accounts for a significant amount of hospital admissions and can quickly progress to the development of delirium tremens (DTs), seizures, and death. Rapid identification and management of alcohol withdrawal syndrome (AWS) is vital and can be managed with a number of different treatment strategies. Diazepam loading is a treatment strategy that utilizes the pharmacokinetics of this agent to achieve a rapid reduction in symptoms followed by sustained benefit over a period of days.ObjectiveThe purpose of this review is to evaluate the role of diazepam loading for AWS.MethodsA literature search of four databases—Pubmed, PsychInfo, Biosis, and Embase—was conducted to identify publications between 1960 and August 2011 that described the use of diazepam loading for the treatment of AWS. Eight trials, both open‐label and controlled trials were identified. Only four randomized controlled‐trials (RCTs) have been published and they are reviewed in this paper.ResultsIncluded trials of hospitalized inpatients found that diazepam loading provided rapid symptom relief as well as reduced the incidence of seizures and duration of DTs. In patients diagnosed with severe DTs, rapidly administered doses of diazepam produced a quick calming effect. While no adverse events resulting from diazepam loading were noted, no formal assessment tool was used to evaluate its safety. Larger randomized controlled‐trials are needed to better evaluate safety outcomes.ConclusionsDiazepam loading is an effective treatment option for hospitalized patients experiencing AWS. Diazepam loading uses the concept of symptom‐triggered therapy, a mainstay of current AWS treatment, while exploiting its prolonged elimination half‐life and eliminating the need for additional pharmacologic therapy. Studies reviewed found diazepam loading significantly improved a number of important outcomes in AWS, including time in DTs, compared to traditional treatment strategies. (Am J Addict 2013;22:113‐118)
Retropharyngeal lymph node dissection in oropharyngeal cancer treated with transoral robotic surgery
Moore, Eric J. , Ebrahimi, Ardalan , Price, Daniel L. , Olsen, Kerry D., Price, Daniel L

Mayo Clinic

The Laryngoscope | January 31, 2013 | Volume: 123 | Issue: 7 | Pages: 1676-1681

10.1002/lary.24009 | PMID 23371397 Get It

Objectives/HypothesisAssess the role of retropharyngeal lymph node dissection in oropharyngeal squamous cell carcinoma treated with transoral robotic surgery (TORS).Study DesignProspective case series.MethodsRetrospective analysis of 72 patients with oropharyngeal squamous carcinoma treated with transoral oropharyngectomy, neck dissection, and retropharyngeal node dissection.ResultsEight of 55 (14.5%) patients with tonsil primaries had retropharyngeal metastases in contrast to none with tongue base primaries. The presence of pathologically positive retropharyngeal nodes was associated with clinical tumor (T) (P=.002) and node (N) stage (P=.007), preoperative computed tomography (CT) (P<.001), and positron emission tomography (PET)‐CT scan (P<.001). The negative predictive value of early T (Tx,1‐2) and N stage (N0‐N2a) was 91.7% and 100%, respectively. Preoperative CT and PET‐CT both yielded a positive predictive value of 100%, while the negative predictive value of imaging was optimized to 95.3% when these modalities were combined.ConclusionsIn patients with tonsil cancer the risk of retropharyngeal metastases is negligible in the presence of clinically T1‐2, N0‐N2a disease and negative CT and PET‐CT. We estimate that 40% of patients meet these criteria and may safely forego treatment of the retropharyngeal nodes. Approximately 10% of patients will have positive imaging and we recommend retropharyngeal node dissection at the time of surgery to treat macroscopic disease. In the remaining patients at risk for retropharyngeal node involvement, adjuvant radiotherapy is generally indicated based on other adverse features, and these nodes may be incorporated into the treatment field.Level of Evidence4. Laryngoscope, 2013
Cardiovascular Risk in Psoriasis: A Population-Based Analysis with Assessment of the Framingham Risk Score
Veetil, Bharath Manu Akkara, Matteson, Eric L. , McEvoy, Marian T., Crowson, Cynthia S. , Myasoedova, Elena , Kremers, Hilal Maradit

Mayo Clinic

Scientifica | January 31, 2013 | Volume: 2013 | Issue: No issue available | Pages: 1-4

10.1155/2013/371569 | PMID 24278773 Get It

Objective. To examine the utility of the Framingham risk score (FRS) in estimating cardiovascular risk in psoriasis.Methods. We compared the predicted 10-year risk of cardiovascular events, namely, cardiovascular death, myocardial infarction, heart failure, percutaneous transluminal coronary angioplasty, and coronary artery bypass grafting using the FRS, to the observed risk of cardiovascular events in a population-based cohort of patients with psoriasis. Patients with incident or prevalent adult-onset psoriasis aged 30–79 years without prior history of cardiovascular disease were included.Results. Among the 1197 patients with predicted risk scores, the median FRS was 6.0%, while the observed 10-year cardiovascular risk was 6.9% (standardized incidence ratio (SIR): 1.14; 95% confidence interval (CI): 0.92–1.42). The SIR was not elevated for women nor for men. The differences between observed and predicted cardiovascular risks in patients <60 years (SIR: 1.01; 95% CI: 0.73–1.41) or ≥60 years (SIR: 1.26; 95% CI: 0.95–1.68) were not statistically significant.Conclusion. There was no apparent difference between observed and predicted cardiovascular risks in patients with psoriasis in our study. FRS reasonably estimated cardiovascular risk in both men and women as well as in younger and older psoriasis patients, suggesting that FRS can be used in risk stratification in psoriasis without further adjustment.
Evaluation of Treatment Benefit in Journal of Clinical Oncology
Goodwin, Pamela J. , Cannistra, Stephen A., Ballman, Karla V. , Small, Eric J.

Mayo Clinic

Journal of Clinical Oncology | January 29, 2013 | Volume: 31 | Issue: 9 | Pages: 1123-1124

10.1200/jco.2012.47.6952 | PMID 23358984 Get It

Symptomatic internal carotid artery medialization: A rare anatomic variant resulting in cough, dysphonia, and dysphagia
Abel, Kathryn M. Van , Carlson, Matthew L. , Moore, Eric J. , Van Abel, Kathryn M

Mayo Clinic

Clinical Anatomy | January 28, 2013 | Volume: 26 | Issue: 8 | Pages: 966-970

10.1002/ca.22178 | PMID 23355276 Get It

Matrix Gla Protein Gene Polymorphism Is Associated With Increased Coronary Artery Calcification Progression
Cassidy‐Bushrow, Andrea E. , Bielak, Lawrence F. , Levin, Albert M. , Sheedy, Patrick F. , Boerwinkle, Eric , Kardia, Sharon L. R., Peyser, Patricia A. , Turner, Stephen T. , Lin, Xihong

Mayo Clinic

Arteriosclerosis, Thrombosis, and Vascular Biology | January 11, 2013 | Volume: 33 | Issue: 3 | Pages: 645-651

10.1161/atvbaha.112.300491 | PMID 23307874 Get It

Objective— Matrix gla protein (MGP) inhibits arterial and cartilaginous calcification. A threonine to alanine (Thr83Ala) polymorphism (codon 83) in MGP is associated with myocardial infarction and femoral artery calcification. We examined the association of the MGP Thr83Ala polymorphism with quantity and progression of coronary artery calcification (CAC), a noninvasive measure of subclinical coronary atherosclerosis. Methods and Results— In 605 participants of the Epidemiology of Coronary Artery Calcification Study, generalized linear mixed models were fit to determine the association of MGP Thr83Ala with CAC quantity and progression. There was a significant additive relation between MGP Thr83Ala and CAC progression ( P =0.001). In the fully adjusted model, every 1 Ala83 allele increase was associated with an estimated 1.9% (95% confidence interval, 0.7%–3.0%) per year since baseline larger increase in CAC quantity. A proxy single nucleotide polymorphism for MGP Thr83Ala (rs6488724) was similarly associated with CAC progression in an independent cohort from the Genetic Epidemiology Network of Arteriopathy (GENOA) study. Conclusion— Increased risk of myocardial infarction associated with MGP ThrAla83 genotype observed elsewhere may be related to faster progression of subclinical coronary atherosclerosis. MGP genotype could be a potential candidate for identifying individuals at increased risk of atherosclerotic disease who would benefit from aggressive primary prevention strategies.
Feline Immunodeficiency Virus Gag Is a Nuclear Shuttling Protein
Kemler, Iris, Saenz, Dyana T. , Poeschla, Eric M.

Mayo Clinic

Journal of Virology | January 10, 2013 | Volume: 87 | Issue: 3 | Pages: 1922-1922

10.1128/jvi.03290-12 Get It

Latestin vitroandin vivomodels of celiac disease
Stoven, Samantha, Murray, Joseph A. , Marietta, Eric, Murray, J A

Mayo Clinic

Expert Opinion on Drug Discovery | January 9, 2013 | Volume: 8 | Issue: 4 | Pages: 445-457

10.1517/17460441.2013.761203 | PMID 23293929 Get It

Pazopanib Enhances Paclitaxel-Induced Mitotic Catastrophe in Anaplastic Thyroid Cancer
Isham, Crescent R., Bossou, Ayoko R., Negron, Vivian , Fisher, Kelly E., Marlow, Laura A. , Lingle, Wilma L., Smallridge, Robert C., Sherman, Eric J. , Copland, John A. , Bible, Keith C. , Kumar, Rakesh , Suman, Vera J. , Marlow, Laura

Mayo Clinic

Science Translational Medicine | January 2, 2013 | Volume: 5 | Issue: 166 | Pages: No page available

10.1126/scitranslmed.3004358 | PMID 23283368 Get It

Pazopanib and paclitaxel produce cytotoxic synergy in thyroid cancer models through inhibition of aurora kinase A.